

WEST

End of Result Set

 Generate Collection

L1: Entry 1 of 1

File: USPT

Aug 6, 2002

US-PAT-NO: 6428785

DOCUMENT-IDENTIFIER: US 6428785 B1

TITLE: Method and composition for treating prostate cancer

DATE-ISSUED: August 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gokcen; Muhamrem	Minneapolis	MN		

US-CL-CURRENT: 424/94.2; 424/94.6, 424/94.62, 424/94.66, 424/94.67, 436/64

CLAIMS:

I claim:

1. A method of treating localized prostate cancer in a mammal comprising intraprostatic administration of a composition comprising a therapeutically effective concentration of collagenase, hyaluronidase, CaCl₂ sub.2, a nonionic surfactant, an antibiotic, and a pharmaceutically acceptable aqueous carrier having a physiologic pH.
2. The method of claim 1, wherein the composition comprises collagenase at a concentration of about 250 to 250,000 U/ml and hyaluronidase at a concentration of about 160 to 160,000 U/ml.
3. The method of claim 2, wherein the composition comprises hyaluronidase at a concentration of about 1,600 to 16,000 U/ml.
4. The method of claim 1, wherein the nonionic surfactant comprises an ethylene oxide ester of a C₁₀-C₂₀ fatty acid, an ethylene oxide ester of a C₈-C₂₂ alkyl alcohol, or a combination thereof.
5. The method of claim 1, wherein the nonionic surfactant comprises alkylenepolyoxezlene.
6. The method of claim 1, wherein the antibiotic comprises gentamicin.
7. The method of claim 1, wherein the intraprostatic administration comprises intralesional injection.
8. The method of claim 1, wherein the intraprostatic administration comprises transurethral injection.
9. The method of claim 1, wherein the intraprostatic administration comprises transurethral injection, transrectal injection, or transperineal injection.
10. The method of claim 1, comprising administering a single injection of about 1 to 50 ml.
11. The method of claim 1, comprising administering a single injection of about 1 to 5 ml.

12. The method of claim 1, comprising administering a depot formulation.

13. The method of claim 1, comprising administering a slow release implant, a microencapsulated composition, or a conjugate with a biodegradable polymer, or conjugate with a prostate-specific immunoglobulin.